Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Niacin

FDA-approved product (capsule, oral), marketed as Niacin, Niacor, Niaspan and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Niacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abdominal pain
  • Acne
  • Anemia (phenotype)
  • Atherosclerosis
  • Cardiovascular disease
  • Chronic kidney disease
  • Coronary artery disease
  • Hypercholesterolemia
  • Hyperlipidemia
  • Iron deficiency anemia
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nicotinic acid and derivatives
FDA pharmacologic class
Nicotinic Acid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Niacin, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis10.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Niacin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Niacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

    NCT00278382 · start 2005-10

    Registered record
    Registry ID
    NCT00278382
    Conditions
    Anaplastic Large Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma
    Interventions
    sorafenib tosylate; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-10
    Completion
    Not recorded
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma
    Interventionsorafenib tosylate; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

    NCT00715273 · start 2001-05-01

    Registered record
    Registry ID
    NCT00715273
    Conditions
    Coronary Artery Disease; Carotid Artery Diseases; Atherosclerosis
    Interventions
    Atorvastatin; Niacin; Colesevelam; Placebo Niacin; Placebo Colesevelam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-05-01
    Completion
    2019-03-01
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Carotid Artery Diseases; Atherosclerosis
    InterventionAtorvastatin; Niacin; Colesevelam; Placebo Niacin +1 more
    PhasePhase 4
    Registry statusCompleted

  • Prenatal Multi-micronutrient Supplementation and Pregnancy Outcome

    NCT00168688 · start 2001-01

    Registered record
    Registry ID
    NCT00168688
    Conditions
    Pregnancy; Birth Weight
    Interventions
    multi micronutrient supplement; MN1; MN2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-01
    Completion
    2002-10
    Enrolment
    2,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy; Birth Weight
    Interventionmulti micronutrient supplement; MN1; MN2
    PhasePhase 1
    Registry statusCompleted

  • TB Nutrition, Immunology and Epidemiology

    NCT00170404 · start 2000-06

    Registered record
    Registry ID
    NCT00170404
    Conditions
    Mycobacterium Tuberculosis
    Interventions
    Folic Acid; Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.; Selenium; Vitamin A
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-06
    Completion
    2005-10
    Enrolment
    887

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Tuberculosis
    InterventionFolic Acid; Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.; Selenium; Vitamin A
    PhasePhase 3
    Registry statusCompleted

  • Carotid Atherosclerosis Regression at Magnetic Resonance Assessment.

    NCT00307307 · start 2000-01

    Registered record
    Registry ID
    NCT00307307
    Conditions
    Established Carotid Atherosclerosis
    Interventions
    Niacin/simvastatin compared to simvastatin alone at 2 doses
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-01
    Completion
    2005-09
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstablished Carotid Atherosclerosis
    InterventionNiacin/simvastatin compared to simvastatin alone at 2 doses
    PhasePhase 4
    Registry statusCompleted